African trypanosomiasis

Oxaboroles

A novel class of antiprotozoal drugs that show promise for the treatment of human African trypanosomiasis (HAT). Acoziborole has been studied in a phase 2/3 trial. Results are being analysed before the submission of a marketing authorization to the European Medicines Agency. The preliminary data suggest that this compound could be efficacious and safe to treat both first- and second-stage HAT.[146]Eperon G, Balasegaram M, Potet J, et al. Treatment options for second-stage gambiense human African trypanosomiasis. Expert Rev Anti Infect Ther. 2014 Nov;12(11):1407-17. https://www.tandfonline.com/doi/full/10.1586/14787210.2014.959496 http://www.ncbi.nlm.nih.gov/pubmed/25204360?tool=bestpractice.com [147]Jacobs RT, Plattner JJ, Nare B, et al. Benzoxaboroles: a new class of potential drugs for human African trypanosomiasis. Future Med Chem. 2011 Aug;3(10):1259-78. http://www.ncbi.nlm.nih.gov/pubmed/21859301?tool=bestpractice.com [148]Jacobs RT, Nare B, Wring SA, et al. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis. 2011 Jun;5(6):e1151. https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0001151 http://www.ncbi.nlm.nih.gov/pubmed/21738803?tool=bestpractice.com [149]Dickie EA, Giordani F, Gould MK, et al. New drugs for human African trypanosomiasis: a twenty first century success story. Trop Med Infect Dis. 2020 Feb 19;5(1):29. https://www.mdpi.com/2414-6366/5/1/29 http://www.ncbi.nlm.nih.gov/pubmed/32092897?tool=bestpractice.com